M&A / Property
EnWave Signs Research and Development License Agreement with Rhizome Food and Farming LLC, a Food Innovation Company Led by Michelin-Starred Chef Dan Barber
## What the news says

Executive Summary
- On April 7 2026 EnWave announced a Research and Development License Agreement with Rhizome Food and Farming LLC, a food‑innovation venture led by Michelin‑starred chef Dan Barber.
- The agreement grants Rhizome rights to use EnWave’s REV™ vacuum‑microwave dehydration technology for R&D purposes; Rhizome purchased a 3.6 kW REV™ machine previously rented by Row7.
- If the joint concepts prove successful, the parties will negotiate a full commercial license that would include royalty‑bearing terms.
- The deal expands EnWave’s existing R&D partner network (Cornell University, Danish Technological Institute, QUT Australia, CNTA Spain) and positions Rhizome to explore “moonshot” ideas in shelf stability, nutrient density and flavor.
Material Impact
- The news is incremental: it adds another research collaborator but does not yet generate equipment sales or royalty revenue.
- No immediate financial uplift is disclosed; the potential upside depends on successful concept validation and a future commercial license negotiation.
- Compared with prior material deals (e.g., royalty‑bearing licenses with Bowen Gumlu, Teagasc, Solve Solutions), this R&D agreement is routine rather than game‑changing.
- Therefore the impact is assessed as Routine - Positive – positive news that expands the pipeline but is already expected as part of EnWave’s partner‑growth strategy.
ENW · Price
Company Overview
EnWave Corporation is a global provider of vacuum microwave dehydration technology (branded REV™). The company’s core offering is the REV™ dryer, which enables rapid, energy‑efficient removal of moisture while preserving nutrients, flavor and color in food, cannabis and other biomass products. EnWave reports over 50 royalty‑generating partners across 26 countries, licensing its technology for applications ranging from fruit snacks to pharmaceutical intermediates.
More from EnWave Corporation
Jun 08, 2026 · 09:00